Astaxanthin Supplementation in Cyclists

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Maastricht University Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01241877
First received: November 15, 2010
Last updated: April 19, 2011
Last verified: April 2011
  Purpose

Background of the study:

Astaxanthin has been shown to be a powerfull anti-oxidant. Health benefits have been shown in animals and humans. Exercise enhancing effects have been shown in animals via enhancement of fat oxidation. We want to examine the effects of 4 weeks of astaxanthin supplementation on fat oxidation and cycling performance in trained cyclists

Objective of the study:

To test the hypothesis that 4 weeks supplementation with astaxanthin will improve fat oxidation and improve exercise performance in trained cyclists

Study design:

Double blind, placebo controlled study.

Study population:

Well trained cyclists between 18-30 years old

Intervention (if applicable):

astaxanthin (20 mg/day) or placebo for 4 weeks

Primary study parameters/outcome of the study:

performance on a time trial after 90 min steady state exercise.

Secundary study parameters/outcome of the study (if applicable):

substrate use plasma glucose plasma lactate plasma free fatty acid plasma astaxanthin

Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):

The risks involved in participating in this experiment are minimal. Astaxanthin has been shown to be safe. Insertion of the catheters in a vein is comparable to a normal blood draw and the only risk is of a small local haematoma.


Condition Intervention
Athletic Performance
Dietary Supplement: astaxanthin
Dietary Supplement: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by Maastricht University Medical Center:

Primary Outcome Measures:
  • time trial performance [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    time trial performance


Secondary Outcome Measures:
  • substrate use [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: November 2010
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: astaxanthin Dietary Supplement: astaxanthin
astaxanthin
Placebo Comparator: placebo Dietary Supplement: placebo
placebo

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy
  • Male
  • Age between 18 and 30 years
  • Endurance trained (≥3 sessions of endurance exercise per week)
  • VO2 max ≥ 50 ml/kg/min
  • Training history of more than one year of ≥3 sessions of endurance exercise per week
  • BMI <25 kg/m2

Exclusion Criteria:

  • Use of medication
  • Smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01241877

Contacts
Contact: Peter Res, MSc +3143381383 peter.res@maastrichtuniversity.nl

Locations
Netherlands
Maastricht University Recruiting
Maastricht, LI, Netherlands, 6229
Contact: Peter Res, MSc    +3143381383    peter.res@maastrichtuniversity.nl   
Sponsors and Collaborators
Maastricht University Medical Center
  More Information

No publications provided by Maastricht University Medical Center

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Peter Res, MUMC
ClinicalTrials.gov Identifier: NCT01241877     History of Changes
Other Study ID Numbers: MEC 10-3-068
Study First Received: November 15, 2010
Last Updated: April 19, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

ClinicalTrials.gov processed this record on July 26, 2014